Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010932 · ClinicalTrials.gov registry record · Phase 3
Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
A Phase 3 study, sponsored by Guerbet.
- Completed
- Registry status
- Phase 3
- Development phase
- 222
- Enrollment target
NCT01010932 is a Phase 3 study that has completed, run by Guerbet. The registered enrollment target is 222 participants.
The verdict
NCT01010932, a Phase 3 study, has completed, sponsored by Guerbet.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 222 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
Interventions
- DRUG Dotarem
- OTHER TOF MRA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010932
The ClinicalTrials.gov registry entry for NCT01010932 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guerbet, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dotarem is the first listed.
NCT01010932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01010932 about?
NCT01010932 is a clinical study titled "Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)". The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
What is the current status of trial NCT01010932?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2009-10. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01010932?
The interventions under investigation include: Dotarem (DRUG), TOF MRA (OTHER).
Who is sponsoring clinical trial NCT01010932?
This trial is sponsored by Guerbet, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.